Designer zinc-fingers

J. Weitzman

DOI: https://doi.org/10.1186/gb-spotlight-20021111-02

IF: 17.906

2002-11-11

Genome Biology

Abstract:

What problem does this paper attempt to address?

Risk Factors for Acute Esophagitis in Non–small-Cell Lung Cancer Patients Treated with Concurrent Chemotherapy and Three-Dimensional Conformal Radiotherapy

Xiong Wei,H. Helen Liu,Susan L. Tucker,Zhongxing Liao,Chaosu Hu,Radhe Mohan,James D. Cox,Ritsuko Komaki

DOI: https://doi.org/10.1016/j.ijrobp.2006.04.022

2006-01-01

Abstract:Purpose: To determine the risk factors for acute esophagitis (AE) in non-small-cell lung cancer (NSCLC) patients treated with concurrent chemotherapy (CCT) and three-dimensional conformal radiotherapy (3D-CRT). Methods and Materials: Clinical data were retrospectively analyzed for 215 NSCLC patients treated with CCT land 3D-CRT during 2000-2003, 127 of whom also had induction chemotherapy (ICT). Carboplatin and paclitaxel were the most commonly used agents for both ICT and CCT. The median prescription dose of radiotherapy was 63.5 Gy in 35 fractions. AE was graded during each treatment week and I-month follow-up visits. The factors related to clinical and disease characteristics, CCT and 3D-CRT treatments, and treatment planning were reviewed and analyzed for their association with Grade >= 3 AE using univariate and multivariate logistic tests.Results: The rate of any grade AE was 93.0% and of Grade >= 3 was 20.5%. Univariate analyses showed that none of the clinical factors was significantly associated with Grade >= 3 AE. However, the mean radiation dose to the esophagus, the absolute esophageal volume treated above 15 Gy (aV15) through aV45 Gy, and the relative esophagus volume treated above 10 Gy (rV10) through rV45 Gy were significant risk factors for Grade >= 3 AE. Only rV20 was retained as the single risk factor in multivariate analyses.Conclusions: The risk of AE in the NSCLC patients treated with CCT and 3D-CRT was primarily determined by dosimetric factors. These factors should be carefully considered during treatment planning to minimize the incidence of AE. (c) 2006 Elsevier Inc.
Severe Radiation-Induced Lymphopenia Affects the Outcomes of Esophageal Cancer: A Comprehensive Systematic Review and Meta-Analysis

Dongjun Dai,Qiaoying Tian,Genhua Yu,Yongjie Shui,Hao Jiang,Qichun Wei

DOI: https://doi.org/10.3390/cancers14123024

2022-01-01

Cancers

Abstract:The aim of the current study was to evaluate the influence of severe radiation-induced lymphopenia (RIL) on the outcomes of esophageal cancer (EC). A systematic review and meta-analysis was performed through the PRISMA guideline. Seventeen studies were included in the current systematic review, with eight included in the meta-analyses. Meta-analyses found that severe RIL was associated with lower pathologic complete response (pCR) rate (odds ratio (OR) = 0.44, 95% confidence interval (CI) = 0.30–0.66, I2 = 0%), inferior overall survival (OS) (hazard ratio (HR) = 1.50, 95% CI = 1.29–1.75, I2 = 6%), and worse progression-free survival (PFS) (HR = 1.70, 95% CI = 1.39–2.07, I2 = 0%) of EC patients. The lymphocyte nadir was found during 4–6 weeks after the start of radiotherapy. The leading dosimetric factors associated with severe RIL included larger PTV, higher dose to heart and body, and higher effective dose to the immune cells (EDIC). Clinical risk factors for RIL mainly comprised lower baseline ALC, higher tumor length and clinical stage, and distal EC. In conclusion, severe RIL might be associated with a lower pCR rate and worse OS and PFS of EC patients. Minimizing the dosimetric risk factors, especially in patients with clinical risk factors, might benefit their outcomes.
Factors associated with acute esophagitis during radiation therapy for lung cancer

Daniel J. Herr,Huiying Yin,Derek Bergsma,Aleksandar F. Dragovic,Martha Matuszak,Margaret Grubb,Michael Dominello,Benjamin Movsas,Larry L. Kestin,Thomas Boike,Amit Bhatt,James A. Hayman,Shruti Jolly,Matthew Schipper,Peter Paximadis

DOI: https://doi.org/10.1016/j.radonc.2024.110349

IF: 6.901

2024-05-30

Radiotherapy and Oncology

Abstract:Introduction Limiting acute esophagitis remains a clinical challenge during the treatment of locally advanced non-small cell lung cancer (NSCLC). Methods Demographic, dosimetric, and acute toxicity data were prospectively collected for patients undergoing definitive radiation therapy +/- chemotherapy for stage II-III NSCLC from 2012 to 2022 across a statewide consortium. Logistic regression models were used to characterize the risk of grade 2 + and 3 + esophagitis as a function of dosimetric and clinical covariates. Multivariate regression models were fitted to predict the 50 % risk of grade 2 esophagitis and 3 % risk of grade 3 esophagitis. Results Of 1760 patients, 84.2 % had stage III disease and 85.3 % received concurrent chemotherapy. 79.2 % of patients had an ECOG performance status ≤ 1. Overall rates of acute grade 2 + and 3 + esophagitis were 48.4 % and 2.2 %, respectively. On multivariate analyses, performance status, mean esophageal dose (MED) and minimum dose to the 2 cc of esophagus receiving the highest dose (D2cc) were significantly associated with grade 2 + and 3 + esophagitis. Concurrent chemotherapy was associated with grade 2 + but not grade 3 + esophagitis. For all patients, MED of 29 Gy and D2cc of 61 Gy corresponded to a 3 % risk of acute grade 3 + esophagitis. For patients receiving chemotherapy, MED of 22 Gy and D2cc of 50 Gy corresponded to a 50 % risk of acute grade 2 + esophagitis. Conclusions Performance status, concurrent chemotherapy, MED and D2cc are associated with acute esophagitis during definitive treatment of NSCLC. Models that quantitatively account for these factors can be useful in individualizing radiation plans.

oncology,radiology, nuclear medicine & medical imaging
Radiobiological modeling of acute esophagitis after radiation therapy of head, neck, and thorax tumors: The influence of chemo-radiation

Mostafa Alizade-Harakiyan,Amir Ghasemi Jangjoo,Tohid Jafari-Koshki,Ali Fatemi,Asghar Mesbahi,AmirGhasemi Jangjoo

DOI: https://doi.org/10.4103/jcrt.jcrt_271_20

2021-01-01

Journal of Cancer Research and Therapeutics

Abstract:Aim: The aim of this study was to evaluate the performance of various radiobiological models in predicting the occurrence of acute esophagitis (AE) during radiation therapy (RT) of head, neck, and thoracic tumors with concurrent and sequential chemotherapy. According to recent studies, the probability of AE following RT by normal tissue complication probability models is predictable.Materials and Methods: A total of 100 patients with nasopharynx, larynx, Hodgkin's lymphoma, spinal metastases, and oral cavity and lung tumors were included in the study. Half of these patients were treated by concurrent chemo-radiotherapy (Con. CRT) and the other half were treated by radiotherapy alone or sequential chemo-radiotherapy (RT + seq. CRT). Radiobiological models of several types were used as follows,: Lyman-generalized equivalent uniform dose (gEUD), Lyman-MED, log-logistic, logit, and logistic. Parameters were estimated using maximum likelihood estimation, and models were compared using Akaike information criteria.Results: Based on follow-up data, the behavior of dose-response curves differed markedly between the Con. CRT and RT + seq. CRT groups. The best fit with clinical results was offered by the Lyman-MED model for the Con. CRT group and the Lyman-gEUD model for the RT + seq. CRT group. Depending on the model used, the parameter of D50 was considerably lower (up to three times) in the Con. CRT group compared to the RT + seq. CRT group.Conclusions: The incidence of AE significantly differed between the two treatment groups in all the models. New parameter estimates could be used for predicting the probability of acute esophagitis after chemo-RT.

oncology
Predicting Severe Radiation Pneumonitis in Patients with Locally- Advanced Non-Small Cell Lung Cancer after Thoracic Radiotherapy: Development and Internal Validation of a Nomogram Based on the Clinical, Hematological and Dose–volume Histogram Parameters

Ying Zhang,Shi-Hong Zhou,Yu-Jie Yan,Leilei Wu,Xiao-Shuai Yuan,Min Hu,Jing-Jing Kang,Chen-Xue Jiang,Yao-Yao Zhu,Shuang-Yan Yang,Rui-Feng Zhao,Jian Hu,Min-Ren Hu,Hui Liu,Liang Liu,Lan Zhao,Ya-Ping Xu

DOI: https://doi.org/10.2139/ssrn.4998748

2024-01-01

Abstract:Purpose Severe radiation pneumonitis (grade≥3 RP) remains an important dose-limiting toxicity after thoracic radiotherapy (RT). This study aimed to investigate risk factors for severe RP in patients with locally-advanced non-small cell lung cancer (NSCLC) after thoracic RT, develop a prediction model to identify high-risk groups and investigate impact of severe RP on overall survival (OS). Methods We retrospectively collected clinical, hematological and dosimetric factors from 351 stage-Ⅲ NSCLC patients after thoracic RT between 2018 and 2022. The primary endpoint was development of severe RP. The secondary endpoint was OS. Logistic regression and least absolute shrinkage and selection operator (LASSO) regression analysis were used to identify risk factors of severe RP. Nomogram was generated based on multivariate regression coefficients. Area under the ROC curve (AUC), calibration curve, and decision curve analysis (DCA) were conducted to validate the model. After a long-term follow-up, OS of patients with RP vs. non-RP and mild RP vs. severe RP groups was analyzed by Kaplan‒Meier method. Results ILD (p<0.001), percentage of contralateral lung volume receiving≥5Gy (contraV5) (P=0.013), percentage of ipsilateral lung volume receiving≥20Gy (ipsiV20)(P=0.039), pre-RT derived neutrophil lymphocyte ratio (dNLR) (P=0.015) and post-RT systemic inflammation response index (SIRI) (p=0.001) were showed to be independent predictors of severe RP and were included in the nomogram. ROC curves revealed the AUC of the nomogram was 0.782. Calibration curves showed favorable consistency, and DCA showed satisfactory positive net benefits of the model. Median follow-up time was 19.8 months (1.4-52.9 months), and cases who developed severe RP showed shorter OS than those developed mild RP (P=0.027). Conclusion We identified that ILD, contraV5(>11%), ipsiV20(>45%), pre-RT dNLR (>1.9) and post-RT SIRI (>3.4) could predict severe RP among patients with locally-advanced NSCLC receiving thoracic RT. Combining these indicators, a nomogram was first built and validated, showing its potential value in clinical practice.
Early Prediction of Acute Esophagitis for Adaptive Radiation Therapy

Sadegh R. Alam,Pengpeng Zhang,Si-Yuan Zhang,Ishita Chen,Andreas Rimner,Neelam Tyagi,Yu-Chi Hu,Wei Lu,Ellen D. Yorke,Joseph O. Deasy,Maria Thor

DOI: https://doi.org/10.1016/j.ijrobp.2021.01.007

2021-01-01

Abstract:Purpose: Acute esophagitis (AE) is a common dose-limiting toxicity in radiation therapy of locally advanced non-small cell lung cancer (LA-NSCLC). We developed an early AE prediction model from weekly accumulated esophagus dose and its associated local volumetric change. Methods and Materials: Fifty-one patients with LA-NSCLC underwent treatment with intensity modulated radiation therapy to 60 Gy in 2-Gy fractions with concurrent chemotherapy and weekly cone beam computed tomography (CBCT). Twenty-eight patients (55%) developed grade >= 2 AE (>= AE2) at a median of 4 weeks after the start of radiation therapy. For early >= AE2 prediction, the esophagus on CBCT of the first 2 weeks was deformably registered to the planning computed tomography images, and weekly esophagus dose was accumulated. Week 1-to-week 2 (w1 -> w2) esophagus volume changes including maximum esophagus expansion (MEex%) and volumes with >= x% local expansions (VEx%; x = 5, 10, 15) were calculated from the Jacobian map of deformation vector field gradients. Logistic regression model with 5-fold cross-validation was built using combinations of the accumulated mean esophagus doses (MED) and the esophagus change parameters with the lowest P value in univariate analysis. The model was validated on an additional 18 and 11 patients with weekly CBCT and magnetic resonance imaging (MRI), respectively, and compared with models using only planned mean dose (MEDPlan). Performance was assessed using area under the curve (AUC) and Hosmer-Lemeshow test (P-HL). Results: Univariately, w1 -> w2 VE10% (P = .004), VE5% (P = .01) and MEex% (P = .02) significantly predicted >= AE2. A model combining MEDW2 and w1 -> w2 VE10% had the best performance (AUC = 0.80; P-HL = 0.43), whereas the MEDPlan model had a lower accuracy (AUC = 0.67; P-HL = 0.26). The combined model also showed high accuracy in the CBCT (AUC = 0.78) and MRI validations (AUC = 0.75). Conclusions: A CBCT-based, cross-validated, and internally validated model on MRI with a combination of accumulated esophagus dose and local volume change from the first 2 weeks of chemotherapy significantly improved AE prediction compared with conventional models using only the planned dose. This model could inform plan adaptation early to lower the risk of esophagitis. Published by Elsevier Inc.
Analysis of clinical and dosimetric factors associated with radiation pneumonitis in patients with lung cancer or esophageal cancer treated with intensity-modulated radiotherapy

YANG Yang,YAN Jing,LIU Juan,REN Wei,KONG Wei-wei,YIN Hai-tao,QIAN Xiao-ping,LIU Bao-rui

DOI: https://doi.org/10.16073/j.cnki.cjcpt.2012.06.011

2012-01-01

Abstract:OBJECTIVE: To evaluate the association between the epidemiological,clinical,and dosimetric factors and radiation pneumonitis in patients with lung cancer or esophageal cancer treated with intensity-modulated radiotherapy.METHODS: Totally 143 patients with lung cancer or esophageal cancer treated with intensity-modulated radiotherapy between January 2007 and December 2010 were analyzed.Radiation pneumonitis was defined and graded according to common terminology criteria for adverse events(CTCAE) version 3.0.The epidemiological,clinical,and dosimetric factors were analyzed using χ2 tests and t test.Univariate and multivariate Logistic regression analyses were used to evaluate the association between related factors and radiation pneumonitis.RESULTS: Among 143 patients,26(18.18%) developed radiation pneumonitis.The 1-4 grade radiation pneumonitis were 13(9.09%),8(5.59%),3(2.10%) and 2(1.40%).Logistic regression analyses showed that previous chemotherapy,previous radiation,concurrent chemotherapy,ECOG score,radiation target,single dose,mean lung dose,V20,V30 and V40 were associated with radiation pneumonitis.CONCLUSION: Some clinical and dosimetric factors are the useful indicators to predict radiation pneumonitis in patients with lung cancer or esophageal cancer treated with intensity-modulated radiotherapy.
Predictive model for acute radiation esophagitis in esophageal carcinoma based on prognostic nutritional index and systemic inflammatory index and its application

Lijun Wu,Wen Li,Xuanxuan Ma,Mengmeng Yuan,Yichun Wang,Shuwen Li

DOI: https://doi.org/10.3892/ol.2024.14730

2024-10-11

Oncology Letters

Abstract:Acute radiation esophagitis (ARE) is a common complication in patients with esophageal cancer undergoing radiotherapy. Therefore, it is important to construct an effective ARE risk‐prediction model for clinical treatment. The present study performed a retrospective analysis of 225 patients with esophageal cancer who received radiotherapy at the First Affiliated Hospital of Anhui Medical University (Hefei, China) from January 2018 to December 2022. Univariate and logistic regression analyses were performed to screen patients with esophageal cancer after radiotherapy. The results revealed that 147 patients developed radiation esophagitis. Logistic regression analysis results demonstrated that the prognostic nutritional index [odds ratio (OR), 0.864; 95% confidence interval (CI), 0.809‐0.924], neutrophil to lymphocyte ratio (OR, 1.795; 95% CI, 1.209‐2.667) and platelet to lymphocyte ratio (OR, 1.011; 95% CI, 1.000‐1.022) were independent predictors of ARE in patients receiving intensity‐modulated conformal radiotherapy for esophagus cancer (P<0.05). A nomogram model for predicting the occurrence of ARE was established based on the three risk factors. The decision curve suggested a high net benefit value when the threshold probability was within 0.25‐1.0. External verification confirmed the reproducibility and generalizability of the nomogram model. In general, the calibration curve of this model was close to the ideal curve and had excellent prediction accuracy. Therefore, it may be used as a new tool for early prediction of the ARE risk.

oncology
Lymphopenia During Definitive Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Association with Dosimetric Parameters and Patient Outcomes.

Hui Xu,Maosheng Lin,Yingying Hu,Li Zhang,Qiaoqiao Li,Jinhan Zhu,Shi Wang,Mian Xi

DOI: https://doi.org/10.1002/onco.13533

2020-01-01

Abstract:BACKGROUND:The objective of this study was to investigate the relationship between clinical characteristics, as well as dosimetric parameters, and the risk of treatment-related lymphopenia in esophageal squamous cell carcinoma (ESCC) treated with definitive chemoradiotherapy (CRT). MATERIALS AND METHODS:Clinical characteristics and dosimetric parameters were collected from 436 patients with ESCC who received definitive CRT from 2010 through 2017. Absolute lymphocyte counts (ALCs) were obtained before, during, and 1 month after CRT. Grade 4 (G4) lymphopenia was defined as ALC <0.2 × 109 /L during CRT. Logistic regression analysis was used to evaluate the effect of each factor on predicting G4 lymphopenia. The relationship between lymphopenia and overall survival (OS) was examined, and a nomogram was developed to predict OS. RESULTS:G4 lymphopenia was observed in 103 patients (23.6%) during CRT. Multivariate analysis indicated that planning target volume (PTV), lung V10 , heart V10 , performance status, and pretreatment lymphopenia were significant risk factors for G4 lymphopenia. Patients with G4 lymphopenia had significantly worse survival than those without. Based on multivariate analysis, clinical TNM stage, radiotherapy modality, pretreatment ALC, and G4 lymphopenia were predictive of OS and were incorporated into the nomogram, yielding a concordance index of 0.71. CONCLUSIONS:G4 lymphopenia during definitive CRT was associated with larger PTVs, higher lung V10 and heart V10 , and worse survival. IMPLICATIONS FOR PRACTICE:The purpose of this study was to investigate the relationship between clinical characteristics, as well as dosimetric parameters, and the risk of treatment-related lymphopenia in 436 patients with esophageal squamous cell carcinoma who received definitive chemoradiotherapy. Grade 4 (G4) lymphopenia was observed in 23.6% of patients during radiotherapy. G4 lymphopenia was associated with larger planning target volumes, higher lung V10 and heart V10 , and worse survival. Then, a nomogram was built based on multivariate analysis, yielding excellent performance to predict overall survival. Prospective studies are needed to investigate potential approaches for mitigating severe lymphopenia, which may ultimately convert into survival benefits.
Baseline nutritional status could be a predictor for radiation esophagitis in esophageal cancer patients undergoing radiotherapy

Jie Dong,Wencheng Zhang,Tian Zhang,Xi Chen,Jingjing Zhao,Yaqi Zeng,Yajun Chen,Xiaoying Wei,Tongda Lei,Ping Wang,Lujun Zhao,Jun Wang,Zhiyong Yuan,Yongchun Song,Ningbo Liu,Kun Wang,Qingsong Pang

DOI: https://doi.org/10.21037/atm-20-4078

IF: 3.616

2020-09-01

Annals of Translational Medicine

Abstract:BACKGROUND: To investigate the relationship between baseline nutrition status and radiation esophagitis in patients with esophageal cancer treated by radiation therapy.METHODS: A retrospective study was performed on 100 patients with esophageal cancer who was treated with definitive chemoradiotherapy, preoperative chemoradiation and definitive radiotherapy at the Tianjin Medical University Cancer Institute and Hospital from October 2018 and October 2019. We documented the clinical characteristics of patients, including tumor location, clinical stage, treatment, radiation dose, gross tumor volume (GTV), planning tumor volume (PTV) and Atkinson's Dysphagia score (ADS), and we recorded the nutrition status before radiation, including Patient-Generated Subjective Global Assessment (PG-SGA), body mass index (BMI), weight loss percentage in 3 mouths (WL), the level of albumin (ALB), hemoglobin (HB), C-reactive protein (CRP) and Glasgow prognostic score (GPS). These factors were correlated with radiation esophagitis using univariate and multivariate regression analyses.RESULTS: Of 100 patients, 44% patients with PG-SGA score ≥9 at baseline, suggesting severe malnutrition, 41% patients developed grade ≥2 radiation esophagitis. In univariate analysis, dose >40 Gy (P=0.015), PTV ≥495 cm3 (P=0.049), PG-SGA score ≥9 (P=0.001), WL ≥10% (P=0.019) and ALB level <35 g/L (P=0.043) were significantly associated with grade ≥2 radiation esophagitis. Multivariate analysis revealed that PG-SGA score ≥9 (P=0.042) was the independent predictor of radiation esophagitis.CONCLUSIONS: Baseline nutritional status associated with development of grade ≥2 radiation esophagitis in patients with esophageal cancer undergoing radiotherapy.

oncology,medicine, research & experimental
Efficacy and Safety of Radiotherapy/chemoradiotherapy Combined with Immune Checkpoint Inhibitors for Locally Advanced Stages of Esophageal Cancer: A Systematic Review and Meta-Analysis

Jing Wu,Rong Deng,Tingting Ni,Qin Zhong,Fei Tang,Yan Li,Yu Zhang

DOI: https://doi.org/10.3389/fonc.2022.887525

IF: 4.7

2022-01-01

Frontiers in Oncology

Abstract:Background Radiotherapy (RT)/Chemoradiotherapy (CRT) are important treatments for all stages of esophageal cancer (EC). The combination of immune checkpoint inhibitors (ICIs) with RT/CRT seems to be promising avenue for the treatment of EC. Therefore, a systematic review and meta-analysis was performed in order to assess the safety and efficacy of RT/CRT and ICI combination therapy for EC patients. Methods PubMed and several other databases were searched (according to specific criteria) to find relevant studies published prior to the 31 st of December 2021. Results 1962 articles were identified for screening, and six trials containing 668 patients were identified and pooled to determine the one- and two-year overall survival (OS), which were 84.5% (95% confidence interval (CI): 69.9%-100%) and 68.3% (95% CI: 49.0%-95.1%), respectively. Additionally, the rate of pooled grade 3-5 adverse reactions was 41.0% (95% CI: 31.2%-51.2%). The rate of specific grade 3-5 adverse reactions are as follows: lymphopenia (36.8%-60%), esophagitis (20%), anastomotic leakage (18%), esophageal fistula (10%), pain (10%), leukopenia (5.3%-10%), esophageal hemorrhage (2.5%-5%), chyle leakage (3%), fatigue (5%), cough (2.7%-5%), diarrhea (2.7%), pulmonary embolism (2.5%) and allergic reaction (2.5%). The pooled rate of pneumonitis of grade 3-5 and grade 1-5 was 0.8% (95% CI: 0.1%-0.16%, I 2 : 0%) and 5.4% (95% CI: 2.0%-14.2%, I 2 : 82%). For thoracic complication, esophagitis was 63.6% (95% CI: 42.4%-80.6%), which appeared to be more frequent with the combination of ICIs to RT/CRT (12%-37.7%). Other thoracic complications include esophageal hemorrhage (2.5%-10%), esophageal fistula (6%-10%) and anastomotic leakage (6%-21%). Additionally, some of the trials did not report cardiac related adverse reactions. The subgroup analyses also revealed that the pooled rate patients with grade 3-5 pneumonitis was higher for CRT/RT with concurrent and sequential ICI treatment (1.9%) than other groups (0.8%). Conclusion This study suggests that the addition of ICIs to RT/CRT for EC patients may be both safe and feasible. However, larger randomized studies are needed to confirm these results.
Analysis of the risk factors of radiation pneumonitis in patients after radiotherapy for esophageal squamous cell carcinoma

Lu Sun,Yan Wang,Lihua Zhu,Jun Chen,Zhifu Chen,Zhiyuan Qiu,Chaoyang Wu

DOI: https://doi.org/10.3389/fonc.2023.1198872

IF: 4.7

2023-11-07

Frontiers in Oncology

Abstract:Objective To predict the risk factors of radiation pneumonitis (RP) in patients with esophageal squamous cell carcinoma (ESCC) who received radiotherapy. Methods From January 2015 to October 2021, 477 ESCC patients were enrolled and were assessed retrospectively. All these patients received radiotherapy for primary lesions or mediastinal metastatic lymph nodes. Clinical efficacy and adverse events (AEs) were observed. Univariate analysis identified clinical and dosimetric factors associated with the development of RP, and multivariate logistic regression analysis identified independent potential risk factors associated with the development of RP. Nomograms were constructed to predict RP based on the results of multivariate logistic regression analysis. Results Among the 477 ESCC patients, the incidence of RP was 22.2%, and the incidence of grade 4 or higher RP was 1.5%. Univariate analysis indicated that chronic obstructive pulmonary disease (COPD), pulmonary infection, leucopenia, PTV volume, V5, V20, V30 and MLD affected the occurrence of RP. The multivariate logistic regression analysis indicated that COPD (OR:1.821, 95%CI:1.111-2.985; P =0.017), pulmonary infection (OR:2.528, 95%CI:1.530-4.177; P <0.001), higher V20 (OR: 1.129, 95% CI:1.006-1.266; P =0.029) were significant independent predictors of RP in ESCC patients. COPD, pulmonary infection, V20 have been integrated for the RP nomogram. The rate of RP was significantly reduced in the V20<21.45% group. Further analysis indicated that the old age, diabetes, higher V20, and higher MLD were risk factors for grade 4 or higher RP. The area under the curve (AUC) value for V20 was 0.73 (95% CI, 0.567-0.893, P < 0.05). Conclusion We have determined the risk factors of RP and grade 4 or higher RP in ESCC patients after radiotherapy. MLD, V20, COPD were independent factors for RP. It was necessary to take measures to reduce or avoid the occurrence of RP for patients with these risk factors at the early stage.

oncology
Association between systemic chemotherapy before chemoradiation and increased risk of treatment-related pneumonitis in esophageal cancer patients treated with definitive chemoradiotherapy.

Shulian Wang,Zhongxing Liao,Xiong Wei,H Helen Liu,Susan L Tucker,Chaosu Hu,Jaffer A Ajani,Alexandria Phan,Stephen G Swisher,Radhe Mohan,James D Cox,Ritsuko Komaki

DOI: https://doi.org/10.1097/JTO.0b013e3181653ca6

IF: 20.121

2008-01-01

Journal of Thoracic Oncology

Abstract:There is limited information on risk factors for treatment-related pneumonitis in esophageal cancer patients.To determine factors associated with treatment-related pneumonitis in esophageal cancer patients treated with definitive chemoradiotherapy.We retrospectively reviewed clinical data from esophageal cancer patients treated with definitive chemoradiotherapy from 2000 to 2003. Demographic, clinical, and treatment-related data were collected for all patients. The time to occurrence of grade > or =2 pneumonitis was calculated from the end of radiotherapy. Univariate analyses were performed to determine the existence of any association between patient demographic, clinical, or treatment characteristics and pneumonitis.In total, 96 patients were included in the study with a median follow-up of 8 months (range, <1-48 months). Among them, 23 patients also received an average of two cycles of systemic chemotherapy before the initiation of concurrent chemoradiation. The incidence of grade > or =2 pneumonitis was 22% at 1 year. Systemic chemotherapy before concurrent chemoradiation was significantly associated with an increased risk of grade > or =2 pneumonitis (p = 0.003), with the 1-year incidence of grade > or =2 pneumonitis for patients with and without systemic chemotherapy being 49 and 14%, respectively. No other clinical or dosimetric factors investigated were associated with the risk of grade > or =2 pneumonitis.Systemic chemotherapy before concurrent chemoradiation was significantly associated with an increased risk of grade > or =2 pneumonitis, suggesting that induction chemotherapy may have sensitized the lung tissue to radiation damage in esophageal cancer patients.
Risk factors for acute exacerbation of interstitial lung disease during chemotherapy for lung cancer: a systematic review and meta-analysis

Zhen Wang,Jiayu Bai,Yujia Liu,Peng Li,Guangyu Jiao

DOI: https://doi.org/10.3389/fonc.2023.1250688

IF: 4.7

2023-10-11

Frontiers in Oncology

Abstract:Purpose The aim of this study was to investigate the risk factors for acute exacerbation (AE) of interstitial lung disease caused by chemotherapy for lung cancer. Methods We searched PubMed, Embase, and The Cochrane Library databases from the establishment of each database to April 2023. Eligible studies were included, and the data on risk factors related to AE caused by chemotherapy in interstitial lung disease were extracted. Results A total of 878 articles were retrieved and 21 met the inclusion criteria. The studies included 1,275 patients with lung cancer combined with interstitial lung disease. The results of the meta-analysis showed four significant risk factors for AE of interstitial lung disease, namely age < 70 years (odds ratio [OR]: 1.98, 95% confidence interval [CI]: 1.05–3.72), forced vital capacity (FVC) (MD=-9.33, 95% CI: -13.7–4.97), usually interstitial pneumonia (UIP) pattern on computed tomography (CT) (OR: 2.11, 95% CI: 1.43–3.11), and serum surfactant protein D (SP-D) (SMD: 0.35, 95% CI: 0.03–0.67). Conclusion When patients with lung cancer complicated with interstitial lung disease are aged < 70 years, have a UIP pattern on CT, have lower FVC values, and have higher serum levels of SP-D, chemotherapy should be carried out with care.

oncology
Risk Factors Associated with Esophageal Fistula after Radiotherapy for Esophageal Squamous Cell Carcinoma

Bing Hu,Feng Jia,Haiyan Zhou,Tao Zhou,Qian Zhao,Yiru Chen,Baosheng Li,Wei Huang

DOI: https://doi.org/10.7150/jca.39033

IF: 3.9

2020-01-01

Journal of Cancer

Abstract:Purpose: The aim of this study was to investigate risk factors for esophageal squamous cell carcinoma (ESCC) treated with radiotherapy (RT) with or without chemotherapy to guide how to reduce the occurrence of esophageal fistula (EF).Methods: 414 patients with ESCC who underwent RT with or without chemotherapy were collected in Shandong Cancer Hospital from February 2012 to June 2018 retrospectively. The clinical characters and dosimetric parameters were recorded. Univariate and multivariate logistic regression analyses were provided to determine the risk factors associated with EF.Results: The cumulative incidences of EF were 11.1% (46/414 patients). The median follow-up period was 15.8 months (range: 0.2-82.6months). The median survival time (MST) of patients with EF was 5.3 months. In univariate analysis, age, T4 stage, N3 stage, chemotherapy regimens, re-RT, ulcerative esophageal cancer (EC), esophageal stenosis, the maximum thickness of the tumor and the length of tumor had a correlation with the prevalence of EF. In multivariable logistic regression analysis, T4 stage, N3 stage, re-RT, ulcerative EC, esophageal stenosis, the maximum thickness of the tumor was confirmed as risk factors for EF.Conclusion: This study revealed that T4 stage, N3 stage, re-RT, ulcerative EC, esophageal stenosis, the maximum thickness of the tumor were risk factors associated with EF. We ought to attach importance to the prevention of EF. Patients with risk factors for EF should be paid close attention.

oncology
Cardiac Substructures Dosimetric Predictors for Cardiac Toxicity After Definitive Radiotherapy in Esophageal Cancer

Guoxin Cai,Chuanbao Li,Jisheng Li,Jianmin Yang,Chengming Li,Liangchao Sun,Jianing Li,Jinming Yu,Xue Meng

DOI: https://doi.org/10.1016/j.ijrobp.2022.08.013

2022-08-15

Abstract:Purpose To investigate the predictive value of the cardiac substructures (CS) dosimetric parameters for cardiac toxicity after definitive radiotherapy in locally advanced esophageal cancer. Methods and Materials Between August 2010 and January 2016, 716 patients with stage II-III esophageal cancer receiving definitive radiotherapy at two institutions were divided into the training (n = 432) and external validation cohorts (n = 284). Dose-volume histogram parameters for the whole heart (WH) and CSs were extracted. Competing risks and Cox regressions analyses were performed. The predictive performance of the models was evaluated using the area under the receiver operating characteristic curve (AUC) and Brier score. Results With a median follow-up of 93 months, 68 patients (15.7%) developed grade ≥ 3 cardiac events (G3+ CEs), at a median of 13.5 months to first event. Multivariable analysis showed left ventricle (LV), left anterior descending (LAD), and mean left circumflex (LCX) variables were significantly associated with G3+ CEs. The AUCs and Brier scores demonstrated favorable predictive accuracies of the models integrating these CS variables when predicting G3+ CEs in the training and validation cohorts. However, compared to the WH variables, the CS variables did not significantly improve the prediction of G3+ CEs. Nevertheless, when G3+ acute coronary syndrome/congestive heart failure (ACS/CHF) CE was the outcome of interest, models based on the LAD or LCX variables were superior to the WH variable models in training and validation cohorts. Conclusions Models based on CSs variables showed favorable predictive accuracy for G3+ CEs. The LAD and LCX variables significantly improved the prediction of G3+ ACS/CHF events compared to the WH variables. Radiation doses to CSs, such as LCX and LAD, should be monitored to help reduce the occurrence of significant CEs in patients with esophageal cancer undergoing definitive radiotherapy.

oncology,radiology, nuclear medicine & medical imaging
Platelet-to-lymphocyte ratio is an independent predictor of chemoradiotherapy-related esophageal fistula in esophageal cancer patients

Dong Han,Jiajia Zhang,Jingjing Zhao,Tongda Lei,Xi Chen,Tian Zhang,Hui Wei,Yong Guan,Jing Wang,Wencheng Zhang,Lujun Zhao,Jun Wang,Zhiyong Yuan,Yongchun Song,Ningbo Liu,Qingsong Pang,Ping Wang

DOI: https://doi.org/10.21037/atm-20-4053

IF: 3.616

2020-09-01

Annals of Translational Medicine

Abstract:BACKGROUND: Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR) are all markers of systemic inflammation response. The role of systemic inflammation in the development of esophageal fistula (EF) has yet to be defined. This study aimed to investigate the predictive value of hematologic measures of inflammation and to set up a predictive model.METHODS: The data of esophageal cancer (EC) patients who received chemoradiotherapy (CRT) in our institution between January, 2015 and January, 2018 were retrospectively collected. The NLR, PLR, and MLR of these enrolled patients were calculated. Univariate and multivariate analyses were performed to find the independent risk factors of EF. Moreover, a nomogram model was developed to predict the probability of fistula occurring in EC patients.RESULTS: For PLR, the optimal cut-off value was 153. Patients with PLR >153 had a higher probability of developing fistula than those with PLR ≤153 (P<0.001). Multivariate analyses revealed that esophageal stenosis, ulcerative tumor, and PLR were independent factors for EF. Subsequently, a novel nomogram was set up with the C-index of 0.77 to predict the risk of developing EF in EC patients who received CRT.CONCLUSIONS: PLR is an independent predictive indicator for EC patients who receive CRT. These findings will help to facilitate individual risk stratification for the development of EF in patients with EC.

oncology,medicine, research & experimental
Abstract 13415: Coronary Calcium Score on Standard of Care Oncologic CT Scans for the Prediction of Adverse Cardiovascular Events in Patients With Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiotherapy

Efstratios KoutroumpakisTING XUJuan Lopez-MatteiSusan GilchristKelsey CorriganTinsu PanYang LuRadhe MohanXiaodong ZhangQing MengRuitao LinTianlin XuAnita M DeswalZhongxing LiaoMD Anderson Cancer Cntr,Houston,TXLee Health Heart and Vascular Inst.,Fort Myers,FLSugara Land,TXHouston,TXUT MD ANDERSON CANCER CENTER,Houston,TX

DOI: https://doi.org/10.1161/circ.146.suppl_1.13415

IF: 37.8

2022-11-01

Circulation

Abstract:Introduction: Chemoradiotherapy (CRT) has been associated with increased incidence of cardiovascular (CV) adverse events (CAE) including coronary events. Coronary calcium scoring (CAC) has shown to predict coronary events beyond the traditional CV risk factors. This study examines whether CAC, measured on standard, non-gated, non-contrast chest CT (NCCT) imaging, predicts the development of CAE in patients with non-small cell lung cancer (NSCLC) treated with CRT. Methods: Patients with NSCLC who were treated with CRT at MD Anderson Cancer Center from 7/2009 until 4/2014 and who had at least one NCCT scan within 6 months from their first CRT were identified. CAC scoring was performed on NCCT scans by an expert cardiologist and a cardiac radiologist following the 2016 SCCT/STR guidelines (software: Syngo.Via, Siemens Healthcare). CAE were graded based on the most recent Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. CAE were also grouped into i. coronary/vascular events ii. arrhythmias iii. heart failure or iv. pericardial disease. All CAE were adjudicated by a board-certified cardiologist. Results: Out of a total of 193 patients, 45% were female and 91% were white. Median age was 65 years (IQR: 58-72) and median BMI was 27 kg/m 2 (24-32). Of 193 patients, 142 (74%) had CAC > 0 Agatston units (AU), 93 (48%) had CAC>100 AU and 36 (49%) CAC >300 AU. Twenty-nine patients (15%) developed a grade >2 CAE during a median follow up of 26.2 months (12.7-53.5). Of those, 11 (38%) were coronary/vascular events. In the multivariate cox regression analysis, controlling for mean heart dose and pre-existing heart disease, higher CAC was independently associated with development of a grade >2 CAE (HR: 1.04, 95% CI: 1.01-1.08, p=0.022) and with worse OS (CAC>100 AU, HR: 1.64, 95% CI: 1.11-2.44, p=0.013). In a sub-analysis evaluating the type of the CAE, it was the coronary/vascular events that were significantly associated with higher baseline CAC (median: 676 AU vs 73 AU, p=0.035). Conclusions: CAEs are frequent in patients with NSCLC treated with CRT. CAC calculated on "standard of care" NCCT can predict the development of CAEs and specifically coronary/vascular events, as well as OS, independently from other traditional risk factors and radiation mean heart dose.

cardiac & cardiovascular systems,peripheral vascular disease
Incidence and Predictors of Pericardial Effusion after Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer

Matthew S. Ning,Linglong Tang,Daniel R. Gomez,Ting Xu,Yangkun Luo,Jinhai Huo,Elie Mouhayar,Zhongxing Liao

DOI: https://doi.org/10.1016/j.ijrobp.2017.05.022

2017-01-01

Abstract:PURPOSE:Findings from Radiation Therapy Oncology Group (RTOG) 0617 suggested that collateral radiation to the heart may contribute to early death in patients receiving chemoradiation therapy for non-small cell lung cancer (NSCLC); however, reports of cardiac toxicity after thoracic radiation therapy (RT) remain limited. Because pericardial disease is the most common cardiac complication of thoracic RT, we investigated the incidence of and risk factors for pericardial effusion (PCE) in patients enrolled in a phase 2 prospective randomized study of intensity modulated RT versus proton therapy for locally advanced NSCLC. METHODS AND MATERIALS:From July 2009 through April 2014, 201 patients were prospectively treated with proton beam therapy or intensity modulated RT to 60 to 74 Gy with concurrent chemotherapy. The primary endpoint (grade ≥2 PCE) was diagnosed on review of follow-up images. Clinical characteristics and cardiac dose-volume parameters associated with PCE were identified via Cox proportional hazards modeling and recursive partitioning analysis of null Martingale residuals. Reproducibility was evaluated in a separate retrospective cohort of 301 patients. RESULTS:The cumulative incidence rates of PCE among patients in the trial were 31.4% at 1 year and 45.4% at 2 years, with a median time to PCE of 8.9 months. Several cardiac dose-volume parameters (eg, V20 [volume receiving ≥20 Gy] to V65 [volume receiving ≥65 Gy]) predicted PCE, but heart volume receiving ≥35 Gy (HV35) was the most strongly associated, with a cutoff volume of 10%. On multivariate analysis, HV35 >10% independently predicted PCE (hazard ratio [HR], 2.14; P=.002), a finding that maintained reproducibility in the retrospective validation cohort. Other factors associated with PCE included receipt of adjuvant chemotherapy (HR, 2.82; P<.001) and prior cardiac disease (HR, 1.68; P=.020). CONCLUSIONS:PCE was common after RT for NSCLC, occurring in nearly half of patients even after moderate radiation doses to the heart. Adjuvant chemotherapy may increase the risk of PCE, and HV35 >10% may identify patients at risk of development of this cardiac toxicity.
Pneumonitis risk after chemoradiotherapy with and without immunotherapy in patients with locally advanced non-small cell lung cancer: A systematic review and meta-analysis

Chong Han,Jingping Qiu,Lu Bai,Tingting Liu,Jun Chen,He Wang,Jun Dang

DOI: https://doi.org/10.1016/j.ijrobp.2024.01.217

IF: 8.013

2024-02-14

International Journal of Radiation Oncology*Biology*Physics

Abstract:Purpose Chemoradiotherapy (CRT) combined with immune checkpoint inhibitors (ICIs) is the standard of care for patients with unresectable and locally advanced non-small cell lung cancer. This study aimed to determine whether the addition of ICIs to CRT is associated with an increased risk of pneumonitis. Methods and Materials PubMed, Embase, Cochrane Library, and Web of Science databases were searched for eligible studies published between January 1, 2015 and July 31, 2023. The outcome of interest was the incidence rate of pneumonitis. A random-effects model was used for statistical analysis. Results A total of 185 studies with 24527 patients were included. The pooled rate of grade ≥2 pneumonitis for CRT plus ICIs was significantly higher than that for CRT alone (29.6%, 95% CI: 25.7%-33.6% vs. 20.2%, 95% CI: 17.7%-22.8%; P < 0.0001), but with no significant differences in rates of grade ≥3, and grade 5 pneumonitis (grade ≥3: 5.7%, 95% CI: 4.8%-6.6% vs. 5.6%, 95% CI: 4.7%-6.5%; P = 0.64; grade 5: 0.1%, 95% CI: 0.0%-0.2% vs. 0.3%, 95% CI: 0.1%-0.4%; P = 0.68). The results from the subgroup analyses of prospective studies, retrospective studies, Asian and non-Asian studies, concurrent CRT (cCRT), and durvalumab consolidation were comparable to the overall results. However, CRT or cCRT plus PD-1 inhibitors not only significantly increased the incidence of grade ≥2 but also that of grade ≥3 pneumonitis compared to CRT alone or cCRT plus PD-L1 inhibitors. Conclusions Durvalumab consolidation after CRT is likely to be associated with a higher incidence of moderate pneumonitis than CRT alone, while CRT plus PD-1 inhibitors also appears to increase the risk of severe pneumonitis. Nevertheless, these findings are based on observational studies, and need to be validated in future large head-to-head studies.

oncology,radiology, nuclear medicine & medical imaging

Designer zinc-fingers

Risk Factors for Acute Esophagitis in Non–small-Cell Lung Cancer Patients Treated with Concurrent Chemotherapy and Three-Dimensional Conformal Radiotherapy

Severe Radiation-Induced Lymphopenia Affects the Outcomes of Esophageal Cancer: A Comprehensive Systematic Review and Meta-Analysis

Factors associated with acute esophagitis during radiation therapy for lung cancer

Radiobiological modeling of acute esophagitis after radiation therapy of head, neck, and thorax tumors: The influence of chemo-radiation

Predicting Severe Radiation Pneumonitis in Patients with Locally- Advanced Non-Small Cell Lung Cancer after Thoracic Radiotherapy: Development and Internal Validation of a Nomogram Based on the Clinical, Hematological and Dose–volume Histogram Parameters

Early Prediction of Acute Esophagitis for Adaptive Radiation Therapy

Analysis of clinical and dosimetric factors associated with radiation pneumonitis in patients with lung cancer or esophageal cancer treated with intensity-modulated radiotherapy

Predictive model for acute radiation esophagitis in esophageal carcinoma based on prognostic nutritional index and systemic inflammatory index and its application

Lymphopenia During Definitive Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Association with Dosimetric Parameters and Patient Outcomes.

Baseline nutritional status could be a predictor for radiation esophagitis in esophageal cancer patients undergoing radiotherapy

Efficacy and Safety of Radiotherapy/chemoradiotherapy Combined with Immune Checkpoint Inhibitors for Locally Advanced Stages of Esophageal Cancer: A Systematic Review and Meta-Analysis

Analysis of the risk factors of radiation pneumonitis in patients after radiotherapy for esophageal squamous cell carcinoma

Association between systemic chemotherapy before chemoradiation and increased risk of treatment-related pneumonitis in esophageal cancer patients treated with definitive chemoradiotherapy.

Risk factors for acute exacerbation of interstitial lung disease during chemotherapy for lung cancer: a systematic review and meta-analysis

Risk Factors Associated with Esophageal Fistula after Radiotherapy for Esophageal Squamous Cell Carcinoma

Cardiac Substructures Dosimetric Predictors for Cardiac Toxicity After Definitive Radiotherapy in Esophageal Cancer

Platelet-to-lymphocyte ratio is an independent predictor of chemoradiotherapy-related esophageal fistula in esophageal cancer patients

Abstract 13415: Coronary Calcium Score on Standard of Care Oncologic CT Scans for the Prediction of Adverse Cardiovascular Events in Patients With Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiotherapy

Incidence and Predictors of Pericardial Effusion after Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer

Pneumonitis risk after chemoradiotherapy with and without immunotherapy in patients with locally advanced non-small cell lung cancer: A systematic review and meta-analysis